Lilly is paying $13 million upfront for exclusive rights to use ImmunoGen's novel camptothecin molecules in ADCs against drug a first batch of drug targets, with an option on a second batch that ...

DAN-222 is a polymeric nanoparticle covalently conjugated with the topoisomerase I inhibitor camptothecin, which has previously demonstrated promising clinical activity in heavily pretreated patients ...

Cleavage of the linker releases and activates the drug payload, an optimized camptothecin with a clinically validated mode of action. Animal studies show that this two-step targeting to-, and ...